GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (FRA:640) » Definitions » COGS-to-Revenue

China Resources Pharmaceutical Group (FRA:640) COGS-to-Revenue : 0.84 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group COGS-to-Revenue?

China Resources Pharmaceutical Group's Cost of Goods Sold for the six months ended in Jun. 2024 was €13,787 Mil. Its Revenue for the six months ended in Jun. 2024 was €16,468 Mil.

China Resources Pharmaceutical Group's COGS to Revenue for the six months ended in Jun. 2024 was 0.84.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. China Resources Pharmaceutical Group's Gross Margin % for the six months ended in Jun. 2024 was 16.28%.

China Resources Pharmaceutical Group COGS-to-Revenue Historical Data

The historical data trend for China Resources Pharmaceutical Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group COGS-to-Revenue Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 0.84 0.85 0.85 0.84

China Resources Pharmaceutical Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.85 0.84 0.85 0.84

China Resources Pharmaceutical Group COGS-to-Revenue Calculation

China Resources Pharmaceutical Group's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=26503.177 / 31426.775
=0.84

China Resources Pharmaceutical Group's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=13786.916 / 16467.553
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group  (FRA:640) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

China Resources Pharmaceutical Group's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 13786.916 / 16467.553
=16.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

China Resources Pharmaceutical Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (FRA:640) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:00867 HKSE:00570 HKSE:02096 HKSE:00512 HKSE:03933 HKSE:06185 HKSE:02005 HKSE:03613 HKSE:01349 HKSE:01558 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
03320:Hong Kong
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
Website
https://www.crpharm.com
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2023, the medical distribution business accounts for 82.6% of its total revenue. CR Pharma's manufacturing business, 17.8% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.

China Resources Pharmaceutical Group Headlines

No Headlines